Nephrogenic Systemic Fibrosis and Gadolinium-Enhanced Magnetic Resonance Imaging: Does a US Food and Drug Administration Alert Influence Practice Patterns in CKD?

2010 ◽  
Vol 56 (3) ◽  
pp. 427-430 ◽  
Author(s):  
Diego R. Martin
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Drug Administration ◽  
Nephrogenic Systemic Fibrosis ◽  
Practice Patterns ◽  
Food And Drug Administration ◽  
Resonance Imaging

Transdermal Patch Administration and Magnetic Resonance Imaging (MRI)—2020

2021 ◽  
pp. 001857872098713
Author(s):  
Janna Afanasjeva ◽  
Michael Gabay ◽  
Thomas Poznanski ◽  
Stefanie Kerns
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Drug Administration ◽  
Hospital Pharmacy ◽  
Transdermal Patch ◽  
Resonance Imaging ◽  
Mri Scan ◽  
Transdermal Patches ◽  
Magnetic Resonance Imaging Mri ◽  
Prescribing Information

This is an update to the 2010 article published in Hospital Pharmacy on safety concerns involving transdermal patches and magnetic resonance imaging (MRI). Since publication of the original article, new brand and generic transdermal medications have become available and notable changes regarding the presence or absence of metallic content among existing transdermal formulations occurred. To update the tables within the article, Food and Drug Administration (FDA)-approved transdermal medications through October 2020 were researched in order to determine metallic content and procedures for reapplication after MRI, if applicable. Readers should consult the prescribing information or manufacturer for the most current information on use of transdermal medications in the MRI setting. Of note, manufacturers have not evaluated the use of transdermal products while patients undergo a MRI scan.

Sign in / Sign up

Export Citation Format

Share Document